YiChang HEC ChangJiang Pharmaceutical : PROGRESS OF COMPLETION OF H SHARE FULL CIRCULATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜 昌 東 陽 光 長 江 藥 業 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

PROGRESS OF COMPLETION OF H SHARE FULL CIRCULATION

References are made to (i) the announcement of the Company dated 22 November 2019 in relation to the Company's participation in the H share full circulation project by converting the Domestic Shares held by the Participating Shareholder into H Shares and listing the same; (ii) the announcement of the Company dated 3 June 2020 in relation to the Company's receipt of an official acceptance letter from CSRC in connection with the Company's application for full circulation of H Shares; (iii) the announcement of the Company dated 19 August 2020 in relation to the granting of the Listing Approval by the Hong Kong Stock Exchange; and (iv) the announcement of the Company dated 2 September 2020 in relation to completion of the H Share full conversion plan (collectively, the ''Announcements''). Unless otherwise indicated, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company has completed the application to China Securities Depository and Clearing Corporation Limited, Shenzhen Branch and maintains a detailed record of the Participating Shareholder's initial holding of the Converted H Shares, which was 226,200,000 shares. The application for a domestic transaction commission code and abbreviation (domestic transaction commission code: 299910; abbreviation: 東陽光藥) submitted by the Company has been confirmed by China Securities Depository and Clearing Corporation Limited, Shenzhen Branch pursuant to the authorization of the Shenzhen Stock Exchange. Guangdong HEC Technology Holding Co., Ltd. (廣東東陽光科技控股股份有限公司), the controlling shareholder of the Company, has opened a specified fund account for H Share ''Full Circulation'' at Huatai Securities Co., Ltd. and has completed the permission activation.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

TANG Xinfa

Chairman

Hubei, the PRC

16 September 2020

As of the date of this announcement, the Board of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive Directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao and Ms. XIANG Ling as independent non-executive Directors.